VivoSeq
Other

Intrathecal Dexmedetomidine

0

Pipeline Programs

3

Active Trials

0

Companies Involved

Intrathecal Dexmedetomidine is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed9 · 56%
Unknown status4 · 25%
Recruiting2 · 13%
Not yet recruiting1 · 6%

Trial Activity

16 trials

Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering
Not yet recruiting··Phase 3·NCT07327879·120 enrolled
Comparing Doses of Intrathecal Dexmedetomidine
Completed··Phase 4·NCT07395271·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)